Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NitroMed thins out R&D

Executive Summary

NitroMed eliminates roughly 30 research and development positions effective March 31. The restructuring is a cost-cutting measure in line with an "increased focus on sales and marketing," the firm says. The move comes just a week after the exit of the company's CEO and CFO as the firm struggles with sluggish sales of its niche heart failure drug BiDil (1"The Pink Sheet" March 27, 2006, p. 14). NitroMed officials say the firm will continue to focus on other nitric-oxide enhancing drugs, including an extended-release formulation of BiDil (isosorbide/hydralazine)...

You may also be interested in...



NitroMed Aims To Revive BiDil With CEO Change, Managed Care Push

NitroMed's strategy for jump-starting sales of BiDil includes renewed efforts to get favorable formulary placement for the heart failure drug

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN

Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel